TabletsMRP Under Process
Official PMBI MRP is being updated for catalog code 2711.
Locate Jan Aushadhi KendraClinical Overview
Naproxen (500mg delayed-release) and Esomeprazole (20mg gastro-resistant) Tablets combines a cardiovascular-safe NSAID with a potent proton pump inhibitor. Naproxen is associated with the lowest cardiovascular thrombotic risk among NSAIDs due to continuous 24-hour platelet COX-1 inhibition; esomeprazole elevates intragastric pH > 4, protecting gastric and duodenal mucosa from NSAID ulceration. Indicated for relief of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis in patients at risk of developing NSAID-associated gastric ulcers.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally 1 tablet twice daily, at least 30 minutes before meals with a full glass of water. Swallow whole; do NOT crush, split, or chew the multi-layer delayed-release tablet.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Dyspepsia, nausea, diarrhea, abdominal pain, headache, flatulence. Rare/Severe: Gastrointestinal bleeding, cardiovascular thrombotic events, acute interstitial nephritis, and hypomagnesemia.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Contraindicated in active peptic ulcer disease, CABG surgery, severe hepatic/renal impairment, and third-trimester pregnancy. Multi-layer tablet must be swallowed whole to preserve sequential release.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or analgesic treatment guidance. Always consult a registered physician or orthopedic specialist before taking pain relievers, anti-inflammatory medications, or anti-arthritic therapies.
Esomeprazole 40mg (Enteric-Coated) + Domperidone 30mg (Sustained Release) Capsules
Esomeprazole (40mg enteric-coated) and Domperidone (30mg sustained-release) combines the pure S-enantiomer of omeprazole with an antiemetic prokinetic. Esomeprazole provides superior bioavailability and acid suppression compared to racemic omeprazole by undergoing lower first-pass hepatic metabolism via CYP2C19. Domperidone provides dopamine D2 receptor antagonism, enhancing lower esophageal sphincter tone and gastroduodenal transit. Indicated for erosive reflux esophagitis, GERD poorly responsive to standard acid suppression, and diabetic gastroparesis with nausea.
Esomeprazole 40mg (Enteric-coated) + Levosulpiride 75mg (Sustained release) Capsules
Esomeprazole (40mg enteric-coated) and Levosulpiride (75mg sustained-release) combines an S-isomer proton pump inhibitor with a central/peripheral prokinetic benzamide. Esomeprazole exerts long-lasting suppression of basal and meal-stimulated gastric acid secretion. Levosulpiride selectively blocks enteric D2 receptors and stimulates 5-HT4 receptors, dramatically improving gastric accommodation and antral motility. Indicated for severe GERD, refractory non-ulcer dyspepsia, and gastroparesis.
Esomeprazole Tablets 40 mg
Omeprazole Gastro-Resistant Capsules (20mg) is a prototypical proton pump inhibitor on the WHO Model List of Essential Medicines. It enters parietal cell canaliculi as a prodrug where acidic pH converts it to a tetracyclic sulfenamide that permanently inactivates H+/K+-ATPase pumps. Indicated for duodenal ulcers, benign gastric ulcers, reflux esophagitis, maintenance therapy of healed erosive esophagitis, and H. pylori eradication (as part of triple therapy).
Naproxen Tablets 500 mg
Naproxen Tablets (250mg, 500mg) is an oral propionic acid NSAID on the WHO Model List of Essential Medicines. It reversibly inhibits both COX-1 and COX-2 enzymes, suppressing prostaglandin synthesis. Due to its long elimination half-life (12 to 17 hours), it provides sustained 24-hour platelet inhibition, conferring the most favorable cardiovascular safety profile among all traditional NSAIDs. Indicated for relief of pain and inflammation in rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute gout, acute tendinitis, bursitis, and primary dysmenorrhea.